

Supplementary Table 1. Cell lines used in the study\*

Name and type of cell line	Source
H446 (SCLC)	ATCC, DTPTR
H187 (SCLC)	Minna JD
H82 (SCLC)	Minna JD
H209 (SCLC)	Minna JD
H69AR (SCLC)	ATCC
HCC33 (SCLC)	Minna JD
H1184 (SCLC)	Minna JD
H1963 (SCLC)	Minna JD
DMS153 (SCLC)	ATCC
H378 (SCLC)	Minna JD
H2107 (SCLC)	Minna JD
H526 (SCLC)	Minna JD
H289 (SCLC)	Minna JD
DMS114 (SCLC)	ATCC
DMS53 (SCLC)	ATCC
H1339 (SCLC)	Minna JD
H69 (SCLC)†	DTPTR
H2195 (SCLC)	Minna JD
DMS79 (SCLC)	ATCC
H146 (SCLC)	ATCC
H1618 (SCLC)	ATCC
H345 (SCLC)	ATCC
H1514 (SCLC)	Minna JD
H1770 (NSCLC)	Minna JD
H1299 (NSCLC)	ATCC
H460 (NSCLC)†	DTPTR
HOP-62 (NSCLC)†	DTPTR
EKVX (NSCLC)†	DTPTR
HOP-92 (NSCLC)†	DTPTR
H522 (NSCLC)†	DTPTR
H23 (NSCLC)†	DTPTR
H322M (NSCLC)†	DTPTR
H226 (NSCLC)†	DTPTR
A549 (NSCLC)†	DTPTR
H727 (NSCLC)	ATCC
H835 (NSCLC)	ATCC
UMC-11 (NSCLC)	ATCC
Y79 (Retinoblastoma)	ATCC
SK-NEP-1 (Wilms' tumor)	ATCC
IMR-32 (Neuroblastoma)†	ATCC
D283Med (Medulloblastoma)	ATCC
SK-N-MC (Neuroepithelioma)	ATCC

WERI-RB1 (Retinoblastoma)	ATCC
SK-N.AS (Neuroblastoma)	ATCC
SK-N-SH (Neuroblastoma)	ATCC
DAOY (Medulloblastoma)	ATCC
SW-13 (Small cell adenocarcinoma)	ATCC
H295R (Adrenocortical carcinoma)	ATCC
H295 (Adrenocortical carcinoma)	ATCC
AsPC-1 (Pancreatic carcinoma)	ATCC
BxPC-3 (Pancreatic carcinoma)	ATCC
Hep3B (Hepatocellular carcinoma)	ATCC
HepG2 (Hepatocellular carcinoma)	ATCC
5637 (Bladder carcinoma)	ATCC
Hs578T (Breast carcinoma)	GTI, Novartis
NCI/ADR-RES (Breast carcinoma)†	DTPTR
MCF7 (Breast carcinoma)†	DTPTR
MDA-MB-231 (Breast carcinoma)†	DTPTR
MDA-MB-435 (Breast ductal carcinoma)†	DTPTR
BT-549 (Breast ductal carcinoma)†	DTPTR
T-47D (Breast ductal carcinoma)†	DTPTR
HeLa (Cervical carcinoma)	ATCC
HT-29 (Colon adenocarcinoma)†	DTPTR
COLO 205 (Colon adenocarcinoma)†	DTPTR
HCC-2998 (Colon carcinoma)†	DTPTR
KM12 (Colon carcinoma)†	DTPTR
HCT 116 (Colon carcinoma)†	DTPTR
HCT-15 (Colon carcinoma)†	DTPTR
SW620 (Colon carcinoma)†	DTPTR
TK-10 (Kidney carcinoma)†	DTPTR
RXF 393 (Kidney carcinoma)†	DTPTR
UO-31 (Kidney carcinoma)†	DTPTR
SN12C (Kidney carcinoma)†	DTPTR
A-498 (Kidney carcinoma)†	DTPTR
ACHN (Kidney carcinoma)†	DTPTR
786-O (Kidney clear cell carcinoma)†	DTPTR
Caki-1 (Kidney clear cell carcinoma)†	DTPTR
SW839 (Kidney clear cell carcinoma)	ATCC
M059K (Glioblastoma)	ATCC
SF-268 (Glioblastoma)†	DTPTR
SNB-75 (Astrocytoma)†	DTPTR
SF295 (Glioblastoma)†	DTPTR
U251 (Glioblastoma)†	DTPTR
SF-539 (Glioblastoma)†	DTTR
SNB-19 (Glioblastoma)†	DTPTR
KK (Glioblastoma)	GTI, Novartis

U-118MG (Glioblastoma, Astrocytoma)†	DTPTR
OVCAR-3 (Ovarian adenocarcinoma)†	ATCC, DT PTR
OVCAR-4 (Ovarian adenocarcinoma)†	DT PTR
OVACR-5 (Ovarian adenocarcinoma)†	DT PTR
OVCAR-8 (Ovarian adenocarcinoma)†	DT PTR
SK-OV-3 (Ovarian adenocarcinoma)†	DT PTR
IGR-OV1 Ovarian carcinoma)†	DT PTR
K-562 (Chronic myelogenous leukemia)†	ATCC, DT PTR
RPMI 8226 (Plasmacytoma)†	DT PTR
HL-60(TB) (Promyleocytic leukemia)†	DT PTR
CCRF-CEM (Acute lymphoblastic leukemia)†	DT PTR
MOLT-4 (Acute lymphoblastic leukemia)†	DT PTR
SR (Large cell lymphoblastic leukemia)†	DT PTR
PC-3 (Prostate adenocarcinoma)†	ATCC, DT PTR
LNCAP.FGC (Prostate adenocarcinoma)	ATCC
DU 145 (Prostate adenocarcinoma)†	ATCC, DT PTR
SK-MEL-2 (Melanoma)†	ATCC, DT PTR
SK-MEL-5 (Melanoma)†	ATCC, DT PTR
SK-MEL-28 (Melanoma)†	ATCC, DT PTR
A375.S2 (Melanoma)	GTI, Novartis
MALME-3M (Melanoma)†	DT PTR
LOXIMVI (Melanoma)†	DT PTR
UACC-62 (Melanoma)†	DT PTR
UACC-257 (Melanoma)†	DT PTR
M14 (Melanoma)†	DT PTR
TT (Thyroid medullary carcinoma)	ATCC
PER.C6 (Fetal retinablasts transformed cell line)	Crucell
HEK293 (Human fetal kidney transformed cell line)	ATCC
Hs1.Tes (Testis cell line)†	DT PTR
HCN-1A (Brain cortical neuronal cells)	ATCC
WI-38 (Lung fibroblasts)	ATCC
IMR-90 (Lung fibroblasts)	ATCC
MRC-5 (Lung fibroblasts)	ATCC
PHH (Primary hepatocytes)	Cambrex
HAEC (Heart and aortic endothelial cells)	Cell Applications Inc.
HAOSMC (Heart and aortic smooth muscle cells)	Cell Applications Inc.
HCAEC (Heart and coronary artery endothelial cells)	Cell Applications Inc.
HCASMC (Heart and coronary artery smooth muscle cells)	Cell Applications Inc.
HRCE (Renal cortical epithelial cells)	Cambrex
HRE (Renal epithelial cells)	Cambrex
HPASMC (Lung smooth muscle cells)	Cell Applications Inc.
NHA (Brain astrocytes)	Cambrex
HUVEC (Umbilical vein endothelial cells)	Cambrex
HMVEC (Microvascular endothelial cells)	Cambrex

Monocytes (Isolated from human blood)	AllCells, LLC.
PBMC (Peripheral blood mononuclear cells)	AllCells, LLC.
NIE-115 (Mouse brain neuroblastoma)	ATCC
BEK (Bovine embryonic kidney cells)	ATCC
ST (Swine testicular cells)	ATCC
PPASMC (Porcine pulmonary artery smooth muscle cells)	Cell Applications Inc.
PCASMC (Porcine carotid artery smooth muscle cells)	Cell Applications Inc.
PAoSMC (Porcine aortic artery smooth muscle cells)	Cell Applications Inc.

\*SCLC = small cell lung carcinoma; NSCLC = Non-small cell lung carcinoma; ATCC = American Type Tissue Collection (Manassas, VA); DTPTR = DTP Tumor Repository at the National Cancer Institute (Frederick, MD); GTI, Novartis = Genetic Therapy Inc.(Gaithersburg, MD); Minna JD, the University of Texas Southwestern Medical Center, Dallas, TX.; Cell Applications Inc. (San Diego, CA); Cambrex (East Rutherford, New Jersey).

†XTT-based cytotoxicity assays carried out at the NCI.